Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials

Abstract Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its “pioneering trials” to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these “pioneering trials”, this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.

Saved in:
Bibliographic Details
Main Authors: LORENZONI,Paulo José, KAY,Cláudia Suemi Kamoi, DUCCI,Renata Dal-Prá, FUSTES,Otto Jesus Hernandez, WERNECK,Lineu Cesar, SCOLA,Rosana Herminia
Format: Digital revista
Published: Academia Brasileira de Neurologia - ABNEURO 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000300179
Tags: Add Tag
No Tags, Be the first to tag this record!